Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts : Results from the prostate biopsy collaborative group

Ankerst, Donna P. ; Boeck, Andreas ; Freedland, Stephen J. ; Stephen Jones, J. ; Cronin, Angel M. ; Roobol, Monique J. ; Hugosson, Jonas ; Kattan, Michael W. ; Klein, Eric A. and Hamdy, Freddie , et al. (2014) In World Journal of Urology 32. p.185-191
Abstract

Objectives: To assess the applicability of the Prostate Cancer Prevention Trial High Grade (Gleason grade ≥ 7) Risk Calculator (PCPTHG) in ten international cohorts, representing a range of populations. Methods: A total of 25,512 biopsies from 10 cohorts (6 European, 1 UK and 3 US) were included; 4 implemented 6-core biopsies, and the remaining had 10 or higher schemes; 8 were screening cohorts, and 2 were clinical. PCPTHG risks were calculated using prostate-specific antigen, digital rectal examination, age, African origin and history of prior biopsy and evaluated in terms of calibration plots, areas underneath the receiver operating characteristic curve (AUC) and net benefit curves. Results: The median AUC of the PCPTHG for high-grade... (More)

Objectives: To assess the applicability of the Prostate Cancer Prevention Trial High Grade (Gleason grade ≥ 7) Risk Calculator (PCPTHG) in ten international cohorts, representing a range of populations. Methods: A total of 25,512 biopsies from 10 cohorts (6 European, 1 UK and 3 US) were included; 4 implemented 6-core biopsies, and the remaining had 10 or higher schemes; 8 were screening cohorts, and 2 were clinical. PCPTHG risks were calculated using prostate-specific antigen, digital rectal examination, age, African origin and history of prior biopsy and evaluated in terms of calibration plots, areas underneath the receiver operating characteristic curve (AUC) and net benefit curves. Results: The median AUC of the PCPTHG for high-grade disease detection in the 10- and higher-core cohorts was 73.5 % (range, 63.9-76.7 %) compared with a median of 78.1 % (range, 72.0-87.6 %) among the four 6-core cohorts. Only the 10-core Cleveland Clinic cohort showed clear evidence of under-prediction by the PCPTHG, and this was restricted to risk ranges less than 15 %. The PCPTHG demonstrated higher clinical net benefit in higher-core compared with 6-core biopsy cohorts, and among the former, there were no notable differences observed between clinical and screening cohorts, nor between European and US cohorts. Conclusions: The PCPTHG requires minimal patient information and can be applied across a range of populations. PCPTHG risk thresholds ranging from 5 to 20 %, depending on patient risk averseness, are recommended for clinical prostate biopsy decision-making.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
keywords
Calibration, Discrimination, High-grade prostate cancer, Net benefit, Risk
in
World Journal of Urology
volume
32
pages
7 pages
publisher
Springer
external identifiers
  • scopus:84893670819
  • pmid:22527674
ISSN
0724-4983
DOI
10.1007/s00345-012-0869-2
language
English
LU publication?
no
id
394de73c-1121-48ea-ac5d-2c4f227a4efd
date added to LUP
2022-12-06 14:19:48
date last changed
2024-06-15 01:53:51
@article{394de73c-1121-48ea-ac5d-2c4f227a4efd,
  abstract     = {{<p>Objectives: To assess the applicability of the Prostate Cancer Prevention Trial High Grade (Gleason grade ≥ 7) Risk Calculator (PCPTHG) in ten international cohorts, representing a range of populations. Methods: A total of 25,512 biopsies from 10 cohorts (6 European, 1 UK and 3 US) were included; 4 implemented 6-core biopsies, and the remaining had 10 or higher schemes; 8 were screening cohorts, and 2 were clinical. PCPTHG risks were calculated using prostate-specific antigen, digital rectal examination, age, African origin and history of prior biopsy and evaluated in terms of calibration plots, areas underneath the receiver operating characteristic curve (AUC) and net benefit curves. Results: The median AUC of the PCPTHG for high-grade disease detection in the 10- and higher-core cohorts was 73.5 % (range, 63.9-76.7 %) compared with a median of 78.1 % (range, 72.0-87.6 %) among the four 6-core cohorts. Only the 10-core Cleveland Clinic cohort showed clear evidence of under-prediction by the PCPTHG, and this was restricted to risk ranges less than 15 %. The PCPTHG demonstrated higher clinical net benefit in higher-core compared with 6-core biopsy cohorts, and among the former, there were no notable differences observed between clinical and screening cohorts, nor between European and US cohorts. Conclusions: The PCPTHG requires minimal patient information and can be applied across a range of populations. PCPTHG risk thresholds ranging from 5 to 20 %, depending on patient risk averseness, are recommended for clinical prostate biopsy decision-making.</p>}},
  author       = {{Ankerst, Donna P. and Boeck, Andreas and Freedland, Stephen J. and Stephen Jones, J. and Cronin, Angel M. and Roobol, Monique J. and Hugosson, Jonas and Kattan, Michael W. and Klein, Eric A. and Hamdy, Freddie and Neal, David and Donovan, Jenny and Parekh, Dipen J. and Klocker, Helmut and Horninger, Wolfgang and Benchikh, Amine and Salama, Gilles and Villers, Arnauld and Moreira, Daniel M. and Schröder, Fritz H. and Lilja, Hans and Vickers, Andrew J. and Thompson, Ian M.}},
  issn         = {{0724-4983}},
  keywords     = {{Calibration; Discrimination; High-grade prostate cancer; Net benefit; Risk}},
  language     = {{eng}},
  pages        = {{185--191}},
  publisher    = {{Springer}},
  series       = {{World Journal of Urology}},
  title        = {{Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts : Results from the prostate biopsy collaborative group}},
  url          = {{http://dx.doi.org/10.1007/s00345-012-0869-2}},
  doi          = {{10.1007/s00345-012-0869-2}},
  volume       = {{32}},
  year         = {{2014}},
}